10-Q: Pulmonx Reports Strong Revenue Growth Amidst Persistent Losses and Strategic Investments

Pulmonx Corporation announced increased revenue for the second quarter and first half of 2025, driven by Zephyr Valve adoption, but reported continued net losses and a reliance on future funding to support ongoing operations and product development.

Summary

• Revenue for the three months ended June 30, 2025, increased by 14.8% to $23.9 million, up from $20.8 million in the prior year period.
• For the six months ended June 30, 2025, revenue grew by 17.1% to $46.4 million, compared to $39.6 million in the same period last year.
• Net loss for the three months ended June 30, 2025, was $15.2 million, a slight improvement from $15.3 million in the prior year.
• Net loss for the six months ended June 30, 2025, increased to $29.6 million, up from $29.1 million in the prior year period.
• Gross margin decreased to 72.1% for the quarter (from 73.7%) and 72.3% for the six months (from 74.1%), primarily due to geographic mix.
• Operating loss improved to $14.8 million for the quarter and $29.4 million for the six months, compared to $15.6 million and $30.2 million respectively in the prior year periods.
• Cash, cash equivalents, and marketable securities totaled $84.2 million as of June 30, 2025.
• The company has an accumulated deficit of $497.2 million as of June 30, 2025.
• Long-term debt, net of discount and issuance costs, stood at $37.1 million as of June 30, 2025.
• The interest-only period for the CIBC Loan was extended through maturity, with full principal repayment due in October 2027.
• The company is engaged in settlement discussions regarding a civil investigative demand from the U.S. Department of Justice related to the Anti-Kickback Statute and False Claims Act, and has recorded an estimated liability.

Sentiment

Score: 4

Explanation: While revenue growth is positive and operating loss improved, the company continues to incur significant net losses, saw a decrease in gross margin, and experienced a notable reduction in its overall cash and marketable securities balance. The explicit need for substantial additional funding and the recorded legal settlement liability contribute to a cautious outlook, indicating ongoing financial challenges despite operational progress.

Positives

• Strong revenue growth of 14.8% for the quarter and 17.1% for the six-month period, driven by increased Zephyr Valve procedure volumes in both U.S. and international markets.
• Operating loss improved by 5.2% for the quarter and 2.6% for the six-month period, indicating better operational efficiency despite increased expenses.
• Net cash used in operating activities decreased to $17.1 million for the six months ended June 30, 2025, from $17.6 million in the prior year period.
• Net cash provided by investing activities significantly improved to $21.8 million for the six months, compared to cash used of $3.3 million in the prior year, primarily due to maturities of marketable securities.
• The interest-only period for the CIBC Loan was extended through its October 2027 maturity, providing greater financial flexibility.
• The U.S. Department of Justice declined to intervene in the Qui Tam Action, and the company has entered into settlement discussions for the related liability.

Negatives

• Continued net losses, with the six-month net loss increasing to $29.6 million from $29.1 million in the prior year.
• Gross margin decreased to 72.1% for the quarter and 72.3% for the six-month period, primarily due to geographic mix.
• Total cash, cash equivalents, and marketable securities decreased to $84.2 million as of June 30, 2025, from $101.5 million as of December 31, 2024.
• Interest income decreased significantly by 44.6% for the quarter and 42.2% for the six-month period due to a lower balance of cash, cash equivalents, and marketable securities.
• Selling, general, and administrative expenses increased by 5.5% for the quarter and 6.3% for the six-month period, driven by advertising, marketing, legal, and personnel costs.
• The company has an accumulated deficit of $497.2 million, indicating a history of significant losses.

Risks

• History of significant net losses, with expectations for continued losses and uncertainty about achieving or sustaining profitability.
• Limited experience marketing and selling the Zephyr Valve solution, which is the company's single primary product.
• Dependence on hospital, physician, and patient adoption of the solution, which may be hindered by unwillingness to change practices, perceived inadequacy of clinical evidence, or patient reluctance.
• Potential failure to receive access to hospital facilities through purchasing contracts or bidding processes.
• Risks associated with Zephyr Valve use, including complications like pneumothorax or death, and contraindications in certain patients, which may limit adoption and lead to product liability claims.
• Inability to achieve and maintain adequate levels of coverage or reimbursement from third-party payors, potentially leaving patients with significant out-of-pocket costs.
• Challenges in recruiting, training, and retaining sales and marketing personnel, and developing broad awareness cost-effectively.
• Limited long-term data regarding the safety and effectiveness of the Zephyr Valve.
• Manufacturing risks due to limited experience in significant commercial quantities and reliance on a limited number of single-source suppliers, making the company vulnerable to supply shortages and price fluctuations.
• Potential compromise of information technology systems or data, or those of third parties, leading to operational interruptions, data breaches, reputational harm, and financial impact.
• Operating results may fluctuate significantly due to various factors, making future results difficult to predict and potentially causing performance to fall below expectations.
• Market size estimates for current and future products may be smaller than anticipated, and declining smoking rates could eventually decrease the patient population.
• Need for substantial additional capital to finance planned operations, which may not be available on acceptable terms and could lead to delays or reductions in commercialization and product development.
• Extensive government regulation and oversight in the U.S. and abroad, with potential for delays, denials, or withdrawal of regulatory approvals/certifications, and enforcement actions for non-compliance.
• Potential involvement in intellectual property litigation, infringement claims, or administrative proceedings that could be costly and interfere with business operations.
• Exposure to anti-bribery, anti-corruption, anti-money laundering, export control, customs, and sanctions laws, with potential for civil or criminal penalties for violations.
• Impact of changes in foreign currency exchange rates on international sales and operating expenses.
• Potential liability related to the privacy of health information, including under HIPAA and GDPR, with risks of regulatory actions, litigation, and fines for non-compliance or security incidents.
• Risks from public health crises and natural disasters impacting operations, supply chain, and clinical studies.
• Potential for acquisitions or investments to divert management attention, result in dilution, or otherwise negatively affect the business.
• Consolidation in the healthcare industry leading to demands for price concessions.
• Challenges in enhancing the solution, expanding indications, and developing additional products.
• Misconduct by employees, consultants, or commercial partners.
• Compliance costs and liabilities related to environmental laws and regulations.
• Changes in patent law diminishing the value of patents.
• Failure of third parties to meet contractual, regulatory, and other obligations.
• Inadequate protection of trademarks and tradenames.
• Patent terms potentially not protecting competitive position for an adequate period.
• Stock price volatility and potential dilution from future capital raises.
• Increased costs and management time associated with operating as a public company.
• Anti-takeover provisions and exclusive forum provisions in charter documents.

Future Outlook

The company expects to continue incurring net losses for the next several years and anticipates requiring substantial additional funding, potentially through future equity and debt financings. Management believes existing cash, cash equivalents, and marketable securities will fund operations for at least the next 12 months. Plans include significant investments in expanding sales and marketing organizations in the U.S., Europe, and Asia Pacific, as well as continued investments in research and development for next-generation products, product enhancements, and regulatory submissions, including the CONVERT II pivotal trial for the AeriSeal System. Additional expenses associated with operating as a public company are also anticipated.

Management Comments

• "Management believes that the Company's existing cash, cash equivalents and marketable securities will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements."
• "We expect to continue to incur net losses for the next several years and we expect to require substantial additional funding, which may include future equity and debt financings."
• "We intend to continue to make significant investments in our sales and marketing organization throughout the United States, Europe and Asia Pacific."
• "We have made, and intend to continue to make, investments in research and development efforts to develop our next generation products and support our future regulatory submissions to increase our addressable market and to expand indications and new markets."

Industry Context

Pulmonx Corporation operates in the medical technology sector, specializing in minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its core solution, comprising the Zephyr Valve, Chartis Pulmonary Assessment System, and LungTraX Platform, has achieved significant regulatory milestones including FDA pre-market approval and CE Mark, and has established reimbursement in major global markets. The AeriSeal System, a product currently in development, has received FDA Breakthrough Device designation and a CE Mark, and is undergoing a global clinical trial (CONVERT II) to support a PMA application. The industry is highly competitive and characterized by rapid technological change, with existing treatments including medical management, lung volume reduction surgery (LVRS), lung transplantation, and other minimally invasive treatments offered by competitors such as Olympus Corporation (Spiration Valve System) and Broncus Medical, Inc. (InterVapor System). The reimbursement landscape is complex, with Medicare covering on a case-by-case basis and various commercial payors having positive coverage policies or approving on a case-by-case basis.

Comparison to Industry Standards

• The filing mentions competitors like Olympus Corporation (Spiration Valve System) and Broncus Medical, Inc. (InterVapor System) as offering alternative or competing treatments for severe emphysema.
• Specific comparable financial results, market share data, or project outcomes for these companies or their products are not provided in the filing to allow for a detailed assessment against global benchmarks.

Management Changes

Legal Proceedings

• Received a civil investigative demand (CID) from the U.S. Department of Justice (USDOJ), Civil Division, in December 2022, in connection with an investigation under the Anti-Kickback Statute and False Claims Act regarding relationships with healthcare providers, medical practices, and hospitals related to sales and marketing of Zephyr Valves.
• In March 2025, the USDOJ informed the company that its investigation was based on a Qui Tam Action and elected not to intervene or pursue the matter further, leading to the unsealing of the Qui Tam Action.
• The company has entered into settlement discussions and recorded an estimated liability for the settlement, which is subject to approval by the USDOJ and other parties.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity capital raises; reliance on stock price appreciation for investment return as no dividends are expected; stock price volatility risk.
• Employees: Potential for increased headcount in sales, marketing, and R&D; impact of management changes; stock-based compensation as a significant part of compensation.
• Customers (Hospitals, Physicians, Patients): Continued availability of Zephyr Valve treatment; ongoing efforts to expand reimbursement coverage; potential for new products (AeriSeal System); risks of complications from procedures; reliance on third-party IT systems for LungTraX Platform.
• Suppliers: Continued reliance on single-source suppliers for critical components, posing supply chain risks.
• Creditors: Debt obligations under the CIBC Loan and COVID-19 Credit Agreement; extension of interest-only period on CIBC Loan provides short-term relief but maintains principal obligation.

Next Steps

• Continue to make significant investments in the sales and marketing organization throughout the United States, Europe, and Asia Pacific to increase adoption of the solution.
• Continue investments in research and development efforts to develop next-generation products and product enhancements.
• Support future regulatory submissions to increase the addressable market and expand indications and new markets.
• Continue progress with the CONVERT II pivotal trial of the AeriSeal System to support a PMA application.
• Engage in settlement discussions for the Qui Tam Action and seek approval from the USDOJ and other parties for the estimated liability.
• Evaluate the impacts of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Evaluate the new guidance from ASU No. 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures, to determine its impact on financial statements and disclosures.

Key Dates

Recommendation

Pulmonx Corporation demonstrates strong revenue growth driven by its core Zephyr Valve product and continued international expansion. The improvement in operating loss indicates some efficiency gains. However, the company remains unprofitable, with an increasing net loss for the six-month period and a declining cash balance. The reliance on a single primary product, ongoing need for substantial additional capital, and the inherent risks associated with medical device commercialization, regulatory compliance, and intellectual property litigation present significant uncertainties. While the extension of the CIBC loan's interest-only period provides liquidity flexibility, the overall financial position suggests a cautious approach. For existing investors, holding the stock to monitor the progress of new product development (AeriSeal System) and the path to profitability is reasonable, given the market potential. For new investors, the current financial profile and capital needs warrant a wait-and-see approach until there is clearer evidence of sustainable profitability and reduced cash burn.

Keywords

Pulmonx Corporation, Medical Technology, Emphysema Treatment, COPD, Zephyr Valve, Chartis Pulmonary Assessment System, LungTraX Platform, AeriSeal System, Minimally Invasive, Interventional Pulmonology, FDA Approval, CE Mark, Healthcare Reimbursement, Clinical Trials, Medical Devices, Biotechnology, Financial Performance, SEC Filing, Quarterly Report, Corporate Governance, Risk Management, Intellectual Property, Sales and Marketing, Supply Chain, Patient Care